期刊文献+

AD模型小鼠海马和小脑Aβ的沉积与相关miRNAs表达的变化 被引量:5

β-amyloid peptide deposition and expression of related miRNAs in the cerebellum of a mouse model of Alzheimer's disease
下载PDF
导出
摘要 目的通过对比观察AD模型小鼠海马与小脑Aβ沉积和相关miRNAs表达的变化,探讨AD模型小鼠小脑是否存在Aβ沉积和相关miRNAs的差异表达。方法选择12月龄大小的APPswe/PS△E9双转基因AD小鼠作为实验组(EG),同月龄的同种系的野生型小鼠C57为对照组(CG),每组各12只。将小鼠脑组织分为左右两部分,右侧脑组织行刚果红染色检测淀粉样物质在海马及小脑的沉积;左侧脑组织分别用于提取海马及小脑的miRNA,应用实时荧光定量PCR方法分别检测两组小鼠海马及小脑组织的miRNA-135a-5p、miRNA-298-5p、miRNA-466b-3p和miR-669f-3p的表达情况。结果刚果红染色:实验组小鼠海马及小脑均可见橘红色的Aβ沉积,对照组小鼠海马及小脑均未见橘红色的Aβ沉积。实时荧光定量PCR:四种miRNAs在实验组海马的表达均低于对照组(P<0.05);miRNA-135a-5p、miRNA-298-5p和miR-669f-3p在实验组小脑的表达低于对照组(P<0.05);miRNA-298-5p和miR-669f-3p在实验组海马的表达低于小脑(P<0.05)。结论 APPswe/PS△E9双转基因AD小鼠小脑中也存在Aβ沉积,其形成可能与miRNA-135a-5p、miRNA-298-5p和miR-669f-3p的表达下调有关。 Objective To investigate the presence of β-amyloid peptide (Aβ) deposition in the cerebellum and the expression of related miRNAs in the cerebellum of a mouse model of Alzheimer disease. Methods Twelve 12-month-old APPswe/PS△E9 double transgenic mice and 12 wild-type C57 mice were sacrificed and the brain tissues were taken for examination. The right hemisphere was stained with Congo red to observe the deposition of amyloid substances, and from the left hemisphere, the hippocampus and the cerebellum were dissected for detecting the expression of miRNA-135a-5p, miRNA-298-5p, miRNA-466b-3p and miR-669f-3p using real-time PCR. Results Congo red staining revealed the presence of Aβdeposition in both the hippocampus and the cerebellum of the transgenic mice but not in the control mice. Real-time PCR showed a significantly lower expression of the 4 miRNAs in the hippocampus in the transgenic mice than in the control mice (P&lt;0.05). The expression of miRNA-135a-5p, miRNA-298-5p, and miR-669f-3p in the cerebellum was significantly lower in the transgenic mice than in the control mice (P&lt;0.05). The expression of miRNA-298-5p and miR-669f-3p in the hippocampus was significantly lower than that in the cerebellum of the transgenic mice (P&lt;0.05). Conclusion Aβdeposition also occurs in the cerebellum of APPswe/PS△E9 double transgenic mice, and its formation might be related to the down-regulation of miRNA-135a-5p, miRNA-298-5p, and miR-669f-3p.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2014年第3期323-328,共6页 Journal of Southern Medical University
基金 湖南省科技厅社会发展支撑计划课题(2012SK3218)
关键词 阿尔茨海默病 淀粉样蛋白 小脑 microRNA Alzheimer disease amyloid microRNA cerebellum
  • 相关文献

参考文献16

  • 1Van Hoesen GW, Augustinack JC, Dierking J, et al. The parahippocampal gyms in Alzheimer's disease.Clinical and preclinical neuroanatomical correlates[J]. Ann N Y Acad Sci, 2000, 911: 254-74.
  • 2Wang HY, D'Andrea MR, Nagele RG. Cerebellar diffuse amyloid plaques are derived from dendritic Abeta42 accumulations in Purkinje cells[J]. Neurobiol Aging, 2002, 23(2): 213-23.
  • 3Sepulveda-Falla D, Matschke J, Bernreuther C, et al. Deposition of hyperphosphorylated tau in cerebellum of PSI E280A Alzheimer's disease[J]. Brain Pathol, 2011, 21(4): 452-63.
  • 4Mavroudis IA, Fotiou DF, Adipepe LF, et al. Morphological changes of the human purkinje cells and deposition of neuritic plaques and neurofibrillary tangles on the cerebellar cortex of Alzheimer's disease[J]. Am J Alzheimers Dis Other Demen, 2010, 25(7): 585-91.
  • 5Lomoio S, L6pez-Gonzilez I, Aso E, et al. Cerebellar amyloid-13 plaques: disturbed cortical circuitry in AI]PP/PS1 transgenic mice as a model of familial Alzheimer's disease [J]. J Alzheimers Dis, 2012, 31(2): 285-300.
  • 6Aso E, Lomoio S, L6pez-Gonzllez I, et al. Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease [J]. Brain Pathol, 2012, 22(5): 636-53.
  • 7丁宇,田密,刘建锋,邓炎尧,李维,奉夏露,侯德仁.APPswe/PS△E9双转基因小鼠脑组织miRNA的表达[J].南方医科大学学报,2012,32(9):1280-1283. 被引量:5
  • 8田密,丁宇,侯德仁,邓炎尧,李维,奉夏露.实时荧光定量PCR检测转基因阿尔茨海默病小鼠脑组织中miRNAs的差异表达[J].南方医科大学学报,2013,33(2):262-266. 被引量:8
  • 9Yakushev I, Landvogt C, Buchholz HG, et al. Choice of reference area in studies of Alzheimer's disease using positron emission tomography with fluorodeoxyglucose-F18 [J]. Psychiatry Res, 2008, 164(2): 143-53.
  • 10Delay C, Mandemakers W, Hebert SS. MicroRNAs in alzheimer's diseas[J]. Neuorbio Dis, 2012, 46(2): 485-90.

二级参考文献33

  • 1Christensen M, Schratt GM. MicroRNA involvement in developmental and functional aspects of the nervous system and neurological diseases[J]. Neurosci Lett, 2009, 466(2): 55-62.
  • 2Junn E, Mouradian MM. MicroRNAs in neurodegenerative diseases and their therapeutic potential [J]. Pharmacol Ther, 2012, 133(2):142-50.
  • 3Satoh J. MieroRNAs and their therapeutic potential for human diseases: aberrant microRNA expression in Alzheimer's disease brains[J]. J Pharmacol Sci, 2010, 114(3): 269-75.
  • 4Provost P. MicroRNAs as a molecular basis for mental retardation, Alzheimer's and priori diseases[J]. Brain Res, 2010, 1338: 58-66.
  • 5Maes OC, Chertkow HM, Wang E, et al. MicroRNA: Implications for Alzheimer disease and other human CNS disorders [J]. Curr Genomics, 2009, 10(3): 154-68.
  • 6Peter T, Wang WX, Rajeev BW, MicroRNAs(miRNAs) in neurodegenerative diseases[J]. Brain Pathol, 2008, 18(1): 130-8.
  • 7Zhou ZD, Chan CH, Ma QH, et al. The roles of amyloid precursor protein(APP) in neurogenesis: Implications to pathogenesis and therapy of Alzheimeri disease[J]. Cell Adhesion Migration, 2011, 5 (4): 280-92.
  • 8Bettens K, Brouwers N, Engelborhs S, et al. APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer disease[J]. Hum Mutat, 2009, 30(8): 1207-13.
  • 9Hebert SS, Horre K, Nicolai L, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression[J]. Proc Natl Acad Sci USA, 2008, 105(17): 6415-20.
  • 10Nelson PT, Wang WX. MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study[J]. J Alzheimers Dis, 2010, 21(1): 75-9.

共引文献10

同被引文献94

  • 1陈万里,曲宁.不同麻醉方式以及麻醉药物对POCD的影响及新进展[J].世界最新医学信息文摘,2019,0(98):110-111. 被引量:1
  • 2杨红,朱德生.盐酸多奈哌齐治疗老年痴呆的疗效研究[J].中国全科医学,2013,16(8):853-856. 被引量:111
  • 3张葳,张昱1,赵晴,杨永梅.β-淀粉样蛋白对D-半乳糖致衰老大鼠学习记忆及海马超微结构的影响[J].吉林大学学报(医学版),2005,31(2):246-248. 被引量:18
  • 4王华丽,于欣.中国阿尔茨海默病的流行病学现状[J].中华全科医师杂志,2006,5(6):358-360. 被引量:47
  • 5贾建平.神经病学[M].北京:人民卫生出版社,2013:389.
  • 6Panza F,Solfrizzi V, Frisardi V, et al. Beyond the neurotransmitter- focused approach in treating Alzheimer's disease:drugs targeting be- ta-amyloid and tau protein [ J ]. Aging Clin Exp Res, 2009,21 ( 6 ) : 386 - 406.
  • 7Ghosh AK, Gemma S,Tang J. Beta-secretase as a therapeutic target for Alzheimer's disease [ J ]. Neurotherapeutics ,2008,5 : 399 - 408.
  • 8Wanngren J,Ottervald J,Parpal S, et al. Second generation γ-secre- tase modulators exhibit different modulation of Notch β and Aβ pro- duction[ J]. J Biol Chem,2012,287 (39) :32640 - 32650.
  • 9Lublin AL,Gandy S. Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease[ J ]. Mt Sinai J Med, 2010,77 ( 1 ) :43 -49.
  • 10Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin(cfioquinol) targeting Abeta amyloid dep- osition and toxicity in Alzheimer disease : a pilot phase 2 clinical trial [ J ]. Arch Neurol,2003,60 ( 12 ) : 1685 - 1691.

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部